News58 seconds ago
Gencurix Announces Clinical Research Results At ASCO 2023 Demonstrating Outstanding Performance of GenesWell BCT, the Company’s Breast Cancer Prognostic Test, Compared to Global Best-Selling Test, OncotypeDX
SEOUL, South Korea, June 4, 2023 /PRNewswire/ — Gencurix (KOSDAQ #229000), a leading provider of cancer molecular diagnostics, announced the release of clinical research results directly...
